|
Cisen Pharmaceutical Co., Ltd. (603367.SS) DCF Valuation |
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cisen Pharmaceutical Co., Ltd. (603367.SS) Bundle
Gain insight into your Cisen Pharmaceutical Co., Ltd. (603367SS) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real (603367SS) data, enabling you to adjust forecasts and assumptions for accurate calculations of Cisen Pharmaceutical's intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,112.8 | 3,674.2 | 3,782.6 | 4,066.1 | 4,462.3 | 4,568.6 | 4,677.4 | 4,788.8 | 4,902.9 | 5,019.7 |
| Revenue Growth, % | 0 | -10.66 | 2.95 | 7.49 | 9.75 | 2.38 | 2.38 | 2.38 | 2.38 | 2.38 |
| EBITDA | 746.9 | 655.6 | 562.6 | 604.3 | 840.0 | 772.7 | 791.1 | 809.9 | 829.2 | 848.9 |
| EBITDA, % | 18.16 | 17.84 | 14.87 | 14.86 | 18.82 | 16.91 | 16.91 | 16.91 | 16.91 | 16.91 |
| Depreciation | 164.2 | 160.0 | 222.6 | 231.2 | 235.8 | 230.3 | 235.8 | 241.4 | 247.1 | 253.0 |
| Depreciation, % | 3.99 | 4.35 | 5.89 | 5.69 | 5.29 | 5.04 | 5.04 | 5.04 | 5.04 | 5.04 |
| EBIT | 582.7 | 495.6 | 339.9 | 373.1 | 604.2 | 542.4 | 555.3 | 568.5 | 582.0 | 595.9 |
| EBIT, % | 14.17 | 13.49 | 8.99 | 9.18 | 13.54 | 11.87 | 11.87 | 11.87 | 11.87 | 11.87 |
| Total Cash | 2,359.0 | 2,536.7 | 2,423.6 | 2,547.7 | 2,621.0 | 2,849.6 | 2,917.4 | 2,986.9 | 3,058.1 | 3,130.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 732.4 | 738.8 | 1,048.5 | 1,271.7 | 1,362.8 | 1,164.6 | 1,192.3 | 1,220.7 | 1,249.8 | 1,279.5 |
| Account Receivables, % | 17.81 | 20.11 | 27.72 | 31.28 | 30.54 | 25.49 | 25.49 | 25.49 | 25.49 | 25.49 |
| Inventories | 600.9 | 572.1 | 594.6 | 580.4 | 708.2 | 694.9 | 711.4 | 728.4 | 745.7 | 763.5 |
| Inventories, % | 14.61 | 15.57 | 15.72 | 14.27 | 15.87 | 15.21 | 15.21 | 15.21 | 15.21 | 15.21 |
| Accounts Payable | 390.6 | 502.1 | 435.0 | 459.7 | 468.0 | 515.9 | 528.1 | 540.7 | 553.6 | 566.8 |
| Accounts Payable, % | 9.5 | 13.67 | 11.5 | 11.31 | 10.49 | 11.29 | 11.29 | 11.29 | 11.29 | 11.29 |
| Capital Expenditure | -103.4 | -202.3 | -51.0 | -35.2 | -17.7 | -97.1 | -99.4 | -101.8 | -104.2 | -106.7 |
| Capital Expenditure, % | -2.51 | -5.51 | -1.35 | -0.86551 | -0.39685 | -2.13 | -2.13 | -2.13 | -2.13 | -2.13 |
| Tax Rate, % | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 | 12.51 |
| EBITAT | 515.1 | 448.8 | 337.9 | 356.5 | 528.6 | 500.5 | 512.4 | 524.7 | 537.1 | 549.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -366.8 | 540.4 | 110.2 | 368.3 | 536.2 | 893.1 | 616.8 | 631.5 | 646.5 | 661.9 |
| WACC, % | 5.07 | 5.07 | 5.08 | 5.07 | 5.06 | 5.07 | 5.07 | 5.07 | 5.07 | 5.07 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 3,000.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 675 | |||||||||
| Terminal Value | 21,990 | |||||||||
| Present Terminal Value | 17,172 | |||||||||
| Enterprise Value | 20,173 | |||||||||
| Net Debt | -813 | |||||||||
| Equity Value | 20,986 | |||||||||
| Diluted Shares Outstanding, MM | 453 | |||||||||
| Equity Value Per Share | 46.29 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Cisen Pharmaceutical Co., Ltd. (603367SS).
- Real-World Insights: Historical performance data and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA margins, and WACC.
- Instant Calculations: Quickly assess how your inputs affect the valuation of Cisen Pharmaceutical Co., Ltd. (603367SS).
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Format: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- Pre-Loaded Data: Historical financial statements and projections for Cisen Pharmaceutical Co., Ltd. (603367SS).
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Instant Results: Watch the intrinsic value for Cisen Pharmaceutical Co., Ltd. (603367SS) update in real time.
- Clear Visual Outputs: Dashboard charts provide insights into valuation results and essential metrics.
- Built for Accuracy: A reliable tool designed for analysts, investors, and finance professionals.
How It Operates
- 1. Access the Template: Download and open the Excel file containing Cisen Pharmaceutical Co., Ltd.'s preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates the intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate multiple forecasts to understand various valuation outcomes.
- 5. Use with Assurance: Present professional valuation insights to bolster your decision-making.
Why Opt for Cisen Pharmaceutical's Calculator?
- Precision: Utilizes authentic Cisen financials to guarantee reliable data.
- Versatility: Crafted to allow users to experiment and adjust inputs effortlessly.
- Efficiency: Avoid the complexities of constructing a financial model from the ground up.
- Expert-Level: Engineered with the accuracy and functionality expected by CFOs.
- Intuitive: Designed for ease of use, even for those new to financial modeling.
Who Should Use This Product?
- Individual Investors: Gain insights for making informed decisions about purchasing or selling Cisen Pharmaceutical Co., Ltd. (603367SS) stock.
- Financial Analysts: Enhance valuation methodologies with user-friendly financial models tailored for Cisen Pharmaceutical Co., Ltd. (603367SS).
- Consultants: Provide clients with timely and accurate valuation insights related to Cisen Pharmaceutical Co., Ltd. (603367SS).
- Business Owners: Learn how companies like Cisen Pharmaceutical Co., Ltd. (603367SS) are valued to inform your own business strategies.
- Finance Students: Explore valuation techniques using practical data and case studies focused on Cisen Pharmaceutical Co., Ltd. (603367SS).
Overview of the Template Content
- Historical Data: Contains Cisen Pharmaceutical’s previous financial reports and foundational projections.
- DCF and Levered DCF Models: Comprehensive templates for assessing the intrinsic value of Cisen Pharmaceutical (603367SS).
- WACC Sheet: Pre-constructed calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust essential variables such as growth rates, EBITDA %, and CAPEX estimates.
- Quarterly and Annual Statements: A thorough analysis of Cisen Pharmaceutical's financial performance.
- Interactive Dashboard: Dynamically visualize valuation outcomes and future forecasts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.